{
    "root": "30b10990-92c4-531b-e063-6294a90a7a27",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Darunavir",
    "value": "20250319",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE (35 .MU.M)",
            "code": "40UAA97IT9"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SILICIFIED MICROCRYSTALLINE CELLULOSE (125 .MICRO.M, HIGH-DENSITY)",
            "code": "GRV5BG8C5N"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "DARUNAVIR",
            "code": "YO603Y8113"
        }
    ],
    "indications": "Darunavir tablets, co-administered with ritonavir (darunavir tablets/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adult and pediatric patients 3 years of age and older\n \n   [see Use in Specific Populations\n  \n   (8.4) and Clinical Studies\n  \n   (14)].",
    "contraindications": "•  Testing: o In treatment-experienced patients, treatment history genotypic and/or phenotypic testing is recommended prior to initiation of therapy with darunavir tablets/ritonavir to assess drug susceptibility of the HIV-1 virus ( 2.1, 12.4) o  Monitor serum liver chemistry tests before and during therapy with  darunavir tablets/ritonavir. ( 2.1, 2.2 , 5.2) • Treatment-naïve adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: 800 mg (one 800 mg tablet) taken with ritonavir 100 mg once daily and with food. (2.3) • Treatment-experienced adult patients with at least one darunavir resistance associated substitution: 600 mg (one 600 mg tablet) taken with ritonavir 100 mg twice daily and with food. (2.3) • Pregnant patients: 600 mg (one 600 mg tablet) taken with ritonavir 100 mg twice daily and with food. (2.4) • Pediatric patients (3 to less than 18 years of age and weighing at least 10 kg): dosage of darunavir tablets and ritonavir is based on body weight and should not exceed the adult dose.  Darunavir tablets should be taken with ritonavir and with food. (2.5) • Darunavir tablets/ritonavir is not recommended for use in patients with severe hepatic impairment. (2.6)",
    "warningsAndPrecautions": "Darunavir 600 mg tablets are available as yellow, oval shaped, biconvex, film-coated tablets debossed with 'V' on one side and '5' on the other side. Each 600 mg tablet contains darunavir amorphous equivalent 600 mg of darunavir. \n    Bottles of 60                                NDC 31722-088-60\n \n                  \n                  \n                  Darunavir 800 mg tablets are available as yellow, oval shaped, biconvex, film-coated tablets debossed with 'V' on one side and '7' on the other side. Each 800 mg tablet contains darunavir amorphous equivalent 800 mg of darunavir \n    Bottles of 30                                NDC 31722-089-30 \n  \n                     \n                     Storage\n                       Store at 20°C to 25°C (68°F to 77°F); with excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. \n  \n                       Keep darunavir tablets out of reach of children.",
    "adverseReactions": "Co-administration of darunavir tablets/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index). These drugs and other contraindicated drugs (which may lead to reduced efficacy of darunavir) are listed below\n \n  [see Drug Interactions\n  \n   (7.3)]. \n \n  Due to the need for co-administration of darunavir tablets with ritonavir, please refer to ritonavir prescribing information for a description of ritonavir contraindications. \n\n \n                  • Alpha 1-adrenoreceptor antagonist: alfuzosin \n    • Anti-gout: colchicine, in patients with renal and/or hepatic impairment \n    • Antimycobacterial: rifampin \n    • Antipsychotics: lurasidone, pimozide \n    • Cardiac Disorders: dronedarone, ivabradine, ranolazine \n    • Ergot derivatives, e.g. dihydroergotamine, ergotamine, methylergonovine  \n    • Herbal product: St. John’s wort\n \n  (Hypericum perforatum)\n                       • Hepatitis C direct acting antiviral: elbasvir/grazoprevir \n    • Lipid modifying agents: lomitapide, lovastatin, simvastatin \n    • Opioid Antagonist: naloxegol \n    • PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension \n    • Sedatives/hypnotics: orally administered midazolam, triazolam"
}